Abstract:• NLRP3 inflammasome is activated with increased NLRP3 acetylation in Tauopathy transgenic mice and AD patients. • Tau promotes NLRP3 acetylation and inflammasome activation dependent on K18 acetyltransferase activity domain. • Tau directly acetylates NLRP3 at K21, K22 and K24 site at its PYD domain and thereby induce inflammasome activation in vitro. • Tau overexpression in mouse hippocampal CA1 neurons induces cognitive impairment, Tau transmission to microglia and microgliosis with NLRP3 acetylation and inflammasome activation. • Competitive binding of a designed TNB peptide to block the interaction of Tau with NLRP3 inhibits the NLRP3 acetylation and downstream inflammasome activation in microglia, thereby alleviating cognitive impairment in mice. Background Alzheimer's disease (AD) and related Tauopathies are characterised by the pathologically hyperphosphorylated and aggregated microtubule‐associated protein Tau, which is accompanied by neuroinflammation mediated by activated microglia. However, the role of Tau pathology in microglia activation or their causal relationship remains largely elusive. Methods The levels of nucleotide‐binding oligomerisation domain (NOD)‐like receptor pyrin domain containing 3 (NLRP3) acetylation and inflammasome activation in multiple cell models with Tau proteins treatment, transgenic mice with Tauopathy, and AD patients were measured by Western blotting and enzyme‐linked immunosorbent assay. In addition, the acetyltransferase activity of Tau and NLRP3 acetylation sites were confirmed using the test‐tube acetylation assay, co‐immunoprecipitation, immunofluorescence (IF) staining, mass spectrometry and molecular docking. The Tau‐overexpressing mouse model was established by overexpression of human Tau proteins in mouse hippocampal CA1 neurons through the adeno‐associated virus injection. The cognitive functions of Tau‐overexpressing mice were assessed in various behavioural tests, and microglia activation was analysed by Iba‐1 IF staining and [18F]‐DPA‐714 positron emission tomography/computed tomography imaging. A peptide that blocks the interaction between Tau and NLRP3 was synthesised to determine the in vitro and in vivo effects of Tau–NLRP3 interaction blockade on NLRP3 acetylation, inflammasome activation, microglia activation and cognitive function. Results Excessively elevated NLRP3 acetylation and inflammasome activation were observed in 3xTg‐AD mice, microtubule‐associated protein Tau P301S (PS19) mice and AD patients. It was further confirmed that mimics of 'early' phosphorylated‐Tau proteins which increase at the initial stage of diseases with Tauopathy, including TauT181E, TauS199E, TauT217E and TauS262E, significantly promoted Tau–K18 domain acetyltransferase activity‐dependent NLRP3 acetylation and inflammasome activation in HEK293T and BV‐2 microglial cells. In addition, Tau protein could directly acetylate NLRP3 at the K21, K22 and K24 sites at its PYD domain and thereby induce inflammasome activation in vitro. Overexpression of human Tau proteins in mouse hippocampal CA1 neurons resulted in impaired cognitive function, Tau transmission to microglia and microgliosis with NLRP3 acetylation and inflammasome activation. As a targeted intervention, competitive binding of a designed Tau–NLRP3‐binding blocking (TNB) peptide to block the interaction of Tau protein with NLRP3 inhibited the NLRP3 acetylation and downstream inflammasome activation in microglia, thereby alleviating microglia activation and cognitive impairment in mice. Conclusions In conclusion, our findings provide evidence for a novel role of Tau in the regulation of microglia activation through acetylating NLRP3, which has potential implications for early intervention and personalised treatment of AD and related Tauopathies.

Extracellular tau stimulates phagocytosis of living neurons by activated microglia via Toll-like 4 receptor–NLRP3 inflammasome–caspase-1 signalling axis

NLRP3 inflammasome activation drives tau pathology

Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer's disease

Hyperphosphorylated Tau Mediates Neuronal Death by Inducing Necroptosis and Inflammation in Alzheimer’s Disease

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Tau induces inflammasome activation and microgliosis through acetylating NLRP3

Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

Stimulation Of Tlr4 Attenuates Alzheimer'S Disease-Related Symptoms And Pathology In Tau-Transgenic Mice

Depletion of microglia and inhibition of exosome synthesis halt tau propagation

NLRP3 Inflammasome-Dependent Increases in High Mobility Group Box 1 Involved in the Cognitive Dysfunction Caused by Tau-Overexpression

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

Hyperphosphorylation of tau protein in the ipsilateral thalamus after focal cortical infarction in rats

G-protein coupled receptors regulates Tauopathy in neurodegeneration

Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy

Complement receptor 4 mediates the clearance of extracellular tau fibrils by microglia

P3‐200: TAU‐MEDIATED CELL DEATH MECHANISMS IN MAPT V337M IPSC‐DERIVED HUMAN NEURONS